CA1 and neoplasm: The fact that SLC-0111 is being trialled in humans has induced the development of SLC-0111 analogues, tested for the potential to inhibit the tumour-associated CA isoforms (CAIX/XII) over the off-target CA isoforms (CA I/II), with the sulfanilamide ureido derivatives being highly effective and some being selective [38].